Sécurité et efficacité du bimekizumab chez les patients atteints de spondylarthrite ankylosante active : résultats à 3 ans d'un essai contrôlé randomisé de phase 2b et de son étude de prolongation en ouvert
Arthritis Rheumatol 2022 doi: 10.1002/art.42282
Bimekizumab is associated with sustained, long-term efficacy in r-axSpA patinets across three years of treatment. In coming to this conclusion, investigators sought to assess the long-term safety, tolerability, and efficacy of bimekizumab in active r-axSpA.